Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kutay Karatepe *Department of Cell Biology, Yale University, New Haven, CT 06520.
Bruna Mafra de Faria *Department of Cell Biology, Yale University, New Haven, CT 06520.
Jian ZhangDepartment of Cell Biology, Yale University, New Haven, CT 06520.
Xinyue ChenDepartment of Cell Biology, Yale University, New Haven, CT 06520.
Hugo PintoDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
Dmitry FyodorovDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
Esen SefikDepartment of Immunobiology, Yale University, New Haven, CT 06520.
Michael A WillcocksonDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.ORCID 0000-0001-6710-1293
Richard A FlavellDepartment of Immunobiology, Yale University, New Haven, CT 06520.ORCID 0000-0003-4461-0778
Arthur I SkoultchiDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.ORCID 0000-0001-5096-8077
Shangqin GuoDepartment of Cell Biology, Yale University, New Haven, CT 06520.ORCID 0000-0003-1157-0423
Funding
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
Yale Cooperative Hematology Specialized Core CenterU54DK106857 · NIDDK · YALE UNIVERSITY · PI JOHN HWA, Diane S Krause · 2015 to 2026
$9.7M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
IMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAININGT32HL007974 · NHLBI · YALE UNIVERSITY · PI JEANNE E HENDRICKSON, Diane S Krause · 2001 to 2026
$8.1M
T32 Institutional Pediatric ResearchT32HD043021 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph W. St. Geme · 2002 to 2026
$6.4M
Molecular definition of cancer cell-of-originDP2GM123507 · NIGMS · YALE UNIVERSITY · PI GUO, SHANGQIN · 2016 to 2016
$2.5M
Functions of Mammalian H1 Linker Histones in Gene Regulation and Chromatin ActivityR01GM147165 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SKOULTCHI, ARTHUR I · 2022 to 2025
$2.1M
Sperm chromatin structure and remodeling during spermiogenesis and fertilizationR01HD114814 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DMITRY V FYODOROV · 2024 to 2026
$1.7M
Driving lymphoid potential in multipotent hematopoietic progenitors by linker histonesR56HL173442 · NHLBI · YALE UNIVERSITY · PI GUO, SHANGQIN · 2024 to 2024
$561k
Timing live cell cycle length in diverse tissuesR21DK128680 · NIDDK · YALE UNIVERSITY · PI GUO, SHANGQIN · 2021 to 2022
$461k
American Society of Hematology (ASH) 22 roundCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Finance Code 001HHS | National Institutes of Health (NIH) R01GM147165HHS | National Institutes of Health (NIH) R01HD114814HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R56HL173442HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) T32HL007974HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R21DK128680HHS | NIH | OSC | Common Fund (NIH Common Fund) DP2GM123507ImCORE AWD0002623NCI NIH HHS P30 CA016359NHLBI NIH HHS R56 HL173442NHLBI NIH HHS T32 HL007974NICHD NIH HHS R01 HD114814NICHD NIH HHS T32 HD043021NIDDK NIH HHS R21 DK128680NIDDK NIH HHS U54 DK106829NIDDK NIH HHS U54 DK106857NIGMS NIH HHS DP2 GM123507NIGMS NIH HHS R01 GM147165
6 · The paper itself
Abstract
Myeloid-biased differentiation of multipotent hematopoietic stem and progenitor cells (HSPCs) occurs with aging or exhaustion. The molecular mechanism(s) responsible for this fate bias remain unclear. Here, we report that linker histone regulates HSPC fate choice at the lymphoid versus myeloid bifurcation. Linker histones package nucleosomes and compact chromatin. HSPCs expressing a doxycycline (dox)-inducible H1.0 transgene favor the lymphoid fate, display strengthened nucleosome organization, and reduced chromatin accessibility at subsets of genomic regions. The genomic regions showing reduced chromatin accessibility host many known marker genes of myeloid-biased HSCs. The transcription factor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Linker histone regulates the myeloid versus lymphoid bifurcation of multipotent hematopoietic stem and progenitors. · full record | OpenQuestion